GlassScriptPhysician profile
Brendan P Sullivan
NPI 1174521140
$6,542.56
in general payments reported to CMS, 2019-2025
18 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,600 · 2020: $258 · 2021: $180 · 2022: $80.44 · 2023: $43.42 · 2024: $162 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375 · Education: $48.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.29 |
| Education | $48.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,506.90 | 2019-2025 | Watchman Flx |
| Novo Nordisk INC | $196.11 | 2020-2025 | Wegovy, Ozempic |
| Amarin Pharma, INC. | $140.68 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $130.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $91.91 | 2019-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $79.71 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $68.11 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $63.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $55.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.72 | 2019-2024 | Jardiance |
| Amgen INC. | $44.66 | 2020-2023 | Repatha |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.99 | 2025 | Breztri |
| Lilly USA, LLC | $15.55 | 2025 | Zepbound |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $14.62 | 2023 | Magnetom Sola |
| Pfizer INC. | $13.56 | 2022 | |
| Esperion Therapeutics, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.